A preliminary analysis of recurrence rates by two methods to estimate the reduction in recurrence rate shows an approximately 80% reduction in recurrence rate in the fully enrolled, 250 patient ...

In response to an FDA request, Sanofi has submitted an expanded access protocol for tolebrutinib in nrSPMS, underscoring the company's commitment to providing eligible patients with access to this ...

These results establish proton therapy as a transforming, safe, and patient-focused solution, poised to redefine the global standard of care for oropharyngeal cancer.

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

These changes will become effective after the market closes on Friday, December 19, 2025.

BlancOne is an Italian-born innovator in dental whitening technologies, known for merging scientific rigour with cosmetic excellence. Distributed exclusively by Byron Medical in Australia, BlancOne is ...

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis. PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint ...

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will host a live webcast ...

SpectraWAVE’s technologies have the potential to significantly increase adoption of coronary intravascular imaging and physiological assessment, especially when combined with Philips’ industry-leading ...

Vaxxas Chair Sarah Meibusch said, “The TGA manufacturing licence marks a significant milestone for Vaxxas as we progress toward commercialising our HD-MAP technology. By reducing cold-chain ...

Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment in the phase IIb study. A total of 187 patients were ...

As per previous communication, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had informed Anavex about a negative trend-vote following its oral examination in ...